Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…
We are now a year-and-a-half into the COVID‑19 pandemic, and rheumaÂtologists and rheumaÂtology professionals are still facing some of the same challenges that began in spring 2020, as well as new ones. Most recently, we learned that COVID‑19 vaccine efficacy is reduced in some patients on immunosuppressive therapies and the need for additional immunization is…
The COVID-19 pandemic changed pretty much every facet of human activity, from home life to social interactions to the workplace. Medicine and research kept up a dizzying pace throughout the pandemic, with physicians and researchers working clinic hours even if they were able to use telemedicine to do some of their work from home. For…
The group’s goals include workforce diversification and inclusive speaker recruitment.
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
ATLANTA—The ACR is actively engaged with the U.S. Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) drug shortage team as they work with the manufacturer to resolve current shortages of tocilizumab (Actemra). Demand for tocilizumab has outpaced supply, with demand increasing after the FDA’s June 24 Emergency Use Authorization (EUA) for…
At the recent Florida Society of Rheumatology meeting, ACR executive vice president Steven Echard, IOM, CAE, emphasized the role of collaborations with state organizations in the ACR’s plans to modernize and expand its activities and offerings.
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
Experts provide insights into spondyloarthropathy, temporomandibular joint involvement and imaging for pediatric patients with JIA.
Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.